Akari Therapeutics (AKTX) Free Cash Flow (2014 - 2026)
Akari Therapeutics (AKTX) reported Free Cash Flow of -$2.5 million for Q1 2026, down 15.72% on a YoY basis from -$3.0 million in Q1 2025, and up 18.18% sequentially from -$3.0 million in Q4 2025.
Akari Therapeutics (AKTX) Free Cash Flow (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Free Cash Flow data on file, last reported at -$2.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 15.72% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$10.9 million (down 2.33% YoY), and the FY2025 full-year result was -$10.6 million, up 15.81% from the prior year.
- Free Cash Flow grew to -$2.5 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q3 2024 to a low of -$4.9 million in Q2 2024.
- A 4-year average of -$3.2 million and a median of -$3.0 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow jumped 51.83% in 2024 and plunged 43.17% in 2025, its largest moves.
- Tracing AKTX's Free Cash Flow over 4 years: stood at -$4.4 million in 2023, then jumped by 51.83% to -$2.1 million in 2024, then sank by 43.17% to -$3.0 million in 2025, then climbed by 18.18% to -$2.5 million in 2026.
- Business Quant data shows AKTX's Free Cash Flow at -$2.5 million in Q1 2026, -$3.0 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 48.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.49 Mn |
| Mar 31, 2026 | -2.49 Mn |
| Dec 31, 2025 | -3.04 Mn |
| Dec 31, 2025 | -3.04 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Mar 31, 2025 | -2.15 Mn |
| Mar 31, 2025 | -2.15 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -4.89 Mn |
| Jun 30, 2024 | -4.89 Mn |
| Mar 31, 2024 | -4.04 Mn |
| Mar 31, 2024 | -4.04 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Dec 31, 2023 | -4.41 Mn |